DAVENPORT FRED B JR
Known title: DirectorCIK: 0001181154
DAVENPORT FRED B JR's purchase track record
DAVENPORT FRED B JR has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/17/2022 | MEDP | $73K | -5.9% | +22.6% | -2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MEDP | ▲ Buy | Option Exercise | 3,858 | $325K | 8/19/2026 | View on chart |
| MEDP | ▲ Buy | Option Exercise | 1,822 | $300K | 8/19/2026 | View on chart |
| MEDP | ▲ Buy | Option Exercise | 1,903 | $255K | 8/19/2026 | View on chart |
| MEDP | ▼ Sell | Open Market | 7,283 | $4.4M | 8/19/2026 | View on chart |
| MEDP | ▲ Buy | Option Exercise | 6,472 | $356K | 10/30/2025 | View on chart |
| MEDP | ▼ Sell | Open Market | 5,972 | $3.5M | 10/30/2025 | View on chart |
| MEDP | ▼ Sell | Open Market | 1,712 | $517K | 4/24/2025 | View on chart |
| MEDP | ▲ Buy | Option Exercise | 4,710 | $269K | 4/24/2025 | View on chart |
| MEDP | ▲ Buy | Open Market | 500 | $73K | 2/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Medpace sees strong bookings but faces valuation and growth concerns
Recent analyst articles note that Medpace reported strong bookings, which support its technical momentum. At the same time, several pieces point out that the company's high valuation and flat pass‑through growth leave limited upside, and that a shorter, cleaner backlog may be misinterpreted as a smaller pipeline. These factors together shape the current market view of the stock.
Medpace sees strong bookings but faces valuation and growth concerns. Recent analyst articles note that Medpace reported strong bookings, which support its technical momentum. At the same time, several pieces point out that the company's high valuation and flat pass‑through growth leave limited upside, and that a shorter, cleaner backlog may be misinterpreted as a smaller pipeline. These factors together shape the current market view of the stock.